In vivoT-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation-Reference-Cited by-同舟云学术

In vivoT-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation

Published:2013-02-28 Issue:4 Volume:88 Page:294-300
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol

Author:

Kanda Yoshinobu¹,Oshima Kumi¹,Kako Shinichi¹,Fukuda Takahiro²,Uchida Naoyuki³,Miyamura Koichi⁴,Kondo Yukio⁵,Nakao Shinji⁵,Nagafuji Koji⁶,Miyamoto Toshihiro⁷,Kurokawa Mineo⁸,Okoshi Yasushi⁹,Chiba Shigeru⁹,Ohashi Yasuo¹⁰,Takaue Yoichi¹¹,Taniguchi Shuichi³

Affiliation:

1. Division of Hematology, Saitama Medical Center; Jichi Medical University; Saitama Japan

2. Stem Cell Transplantation Division; National Cancer Center Hospital; Tokyo Japan

3. Department of Hematology; Toranomon Hospital; Minato-Ku Tokyo Japan

4. Department of Hematology; Japanese Red Cross Nagoya First Hospital; Nagoya Japan

5. Cellular Transplantation Biology; Kanazawa University Graduate School of Medical Science; Japan

6. Division of Hematology and Oncology, Department of Medicine; Kurume University School of Medicine; Japan

7. Department of Medicine and Biosystemic Science; Kyushu University Graduate School of Medical Sciences; Fukuoka Japan

8. Department of Hematology and Oncology, Graduate School of Medicine; University of Tokyo; Tokyo Japan

9. Department of Hematology; University of Tsukuba; Tsukuba Japan

10. Department of Biostatistics, School of Public Health; University of Tokyo; Tokyo Japan

11. Institute for Research, St. Luke's International Hospital; Tokyo Japan

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23392/fullpdf

Reference30 articles.

1. Alemtuzumab for the prevention and treatment of graft-versus-host disease;Kanda;Int J Hematol,2011

2. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation;Kottaridis;Blood,2000

3. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen;Chakraverty;Blood,2002

4. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia;Tauro;J Clin Oncol,2005

5. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission;Patel;Haematologica,2009

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis;International Journal of Hematology;2022-01-14

2. Pre-transplant conditioning regimens in allogeneic transplantation for patients with aplastic anemia;Japanese Journal of Transplantation and Cellular Therapy;2022

3. Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation;Bone Marrow Transplantation;2021-09-10

4. HLA-mismatched haploidentical transplantation using low-dose alemtuzumab;Journal of Hematopoietic Cell Transplantation;2021

5. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60–69 years with myelodysplastic syndrome;Annals of Hematology;2019-03-11